A combined analysis of five observational studies evaluating the efficacy and tolerability of bimatoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension by Pfennigsdorf, Stefan et al.
© 2013 Pfennigsdorf et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article 
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Ophthalmology 2013:7 1219–1225
Clinical Ophthalmology
A combined analysis of five observational  
studies evaluating the efficacy and tolerability  
of bimatoprost/timolol fixed combination  
in patients with primary open-angle glaucoma  
or ocular hypertension
Stefan Pfennigsdorf1
Leo de Jong2
Stefan Makk3
Yvette Fournichot4
Alain Bron5
Robert J Morgan-Warren6
John Maltman6
1Ophthalmology Practice, Polch, 
Germany; 2Academic Medical 
Center, University of Amsterdam, 
Amsterdam, Netherlands; 
3Ophthalmology Practice, Graz, 
Austria; 4Ophthalmology Practice, 
Schlieren, Switzerland; 5Department of 
Ophthalmology, University Hospital, 
Dijon, France; 6Allergan Ltd,  
Marlow, UK
Correspondence: Stefan Pfennigsdorf 
Marktplatz 13, 56751 Polch, Germany 
Tel +49 2654 964515 
Fax +49 2654 964516 
Email pfennigsdorf@me.com
Objective: The aim of this study was to evaluate the safety and efficacy of a fixed combination 
of bimatoprost 0.03% and timolol (BTFC) in a clinical setting, in a large sample of patients 
with primary open-angle glaucoma or ocular hypertension and insufficient intraocular pressure 
(IOP) lowering on prior therapy.
Methods: Patient data were combined (n = 5556) from five multicenter, observational, non-
controlled, open-label studies throughout Europe. Patients were identified from 830 sites in 
Austria, France, Germany, The Netherlands, and Switzerland. Assessments were made at 
baseline, 6 weeks (in Austrian, German and Swiss centers), and 12 weeks in all centers.
Results: BTFC lowered mean IOP from baseline by 5.4 mmHg over the 12-week duration 
of the studies (P , 0.0001). At study entry, 92.9% of patients were receiving another ocular 
hypotensive medication. In patients with no previous treatment (n = 311), BTFC reduced IOP 
by −9.1 mmHg, corresponding to a reduction from baseline of 36.4% (P , 0.0001). In patients 
receiving prior therapy of a prostaglandin analog, a β-blocker, or a fixed combination, BTFC 
reduced IOP by a further 24.5%, 25.9%, and 21.4%, respectively. The majority of patients 
(90.3%) reported no adverse events. The most common adverse events were conjunctival 
 hyperemia (3.2%) and eye irritation (2.8%). BTFC was rated as “good” or “very good” by 92.5% 
of physicians and 88.0% of patients. Most patients (96.3%) were equally or more compliant 
with BTFC than with their previous treatment.
Conclusion: In routine clinical practice, BTFC achieved consistent IOP lowering in both 
previously treated and untreated patients with primary open-angle glaucoma or ocular 
 hypertension. BTFC was associated with significant IOP reductions, good tolerability, and 
good compliance.
Keywords: bimatoprost 0.03%, intraocular pressure, ocular hypotensive medication, 
 prostaglandin analog, β-blocker
Introduction
Elevated intraocular pressure (IOP) increases the risk that patients with ocular hyperten-
sion (OHT) will develop primary open-angle glaucoma (POAG)1 and that those with 
glaucoma will experience disease progression.2–5 Risk factors for progressive loss of 
visual field in glaucoma include increased age, corneal thickness, female sex, abnormal 
baseline anticardiolipin antibody levels as well as raised IOP.1,2 However, lowering 
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IOP is currently the only proven method for preserving visual 
function and reducing the rate of progression in glaucoma 
disease.5–7 In a Canadian observational study to determine the 
impact of risk factors on the rates of visual field change in 
glaucoma, a reduction in median IOP of 20% in patients who 
progressed was associated with a significant 70% decrease 
in the median rate of visual field progression.7
While single medications that lower IOP are common 
first-line therapy for POAG and OHT patients, monotherapy 
does not adequately control IOP long-term for many patients, 
thus multiple therapies are required.4 The addition of one or 
more drugs to the therapeutic regimen (adjunctive therapy) 
increases the dosing frequency, which has been associated 
with reduced patient persistence, leading to poor adherence.8 
Advantages of fixed combination (FC) therapy over therapy 
with unfixed combinations may include greater convenience, 
fewer side effects, and thus better tolerability, leading to 
improved patient compliance.8,9
The FC of bimatoprost 0.03% and timolol 0.5% (BTFC; 
Ganfort®, Allergan, Irvine, CA, USA) provides greater 
IOP reduction than prostaglandin monotherapy10 and is as 
effective as its individual components used adjunctively.11 
Compared with its individual components as monotherapy in 
patients with bilateral glaucoma or OHT, BTFC achieved sig-
nificantly greater reduction in IOP than bimatoprost 0.03% or 
timolol alone.12 In randomized clinical trials, BTFC provided 
greater overall IOP reduction from baseline compared with 
latanoprost/timolol (LT) or travoprost/timolol (TT) FC.13–15 
These trials were included in a meta-analysis of 20 clinical 
trials that suggested BTFC had a greater overall ability to 
lower IOP than LTFC or TTFC.16 Reports of treatment with 
BTFC in clinical practice have confirmed significant IOP 
reductions as well as good adherence and tolerability.17 The 
present combined analysis of five studies aimed to assess the 
safety and IOP-lowering efficacy of BTFC in routine clinical 
practice in a large number of patients with POAG or OHT 
with insufficient IOP lowering on prior therapy.
Methods
Study design
This was a combined analysis of five multicenter, prospec-
tive, observational, non-interventional, non-randomized, 
open-label studies (Figure 1). A total of 830 sites in Austria, 
France, Germany, The Netherlands and Switzerland were 
identified. Patients were treated with BTFC at a dose deter-
mined by the treating physician and guided by the summary 
of product characteristics, which recommends that BTFC is 
applied daily to each affected eye.18 There was no washout 
period for patients on prior therapy before the beginning of 
BTFC treatment, as this was an observational study.
The primary efficacy outcome was mean change in IOP 
(measured using contact tonometry) in each eye from baseline 
to the end of the study (approximately 12 weeks, based on 
routine clinical practice). Efficacy was also assessed in terms 
of target IOP, which was individually set for each patient 
by their treating physician, and a physician-reported assess-
ment of BTFC in terms of IOP reduction using a four-point 
scale: “very good,” “good,” “moderate,” and “poor.” The 
visit schedule was based on routine clinical practice in each 
country: three visits were arranged in Austria, Germany, and 
Switzerland (a baseline visit, a follow-up visit at 6 weeks, and 
a final visit), and two visits in France and The Netherlands 
(baseline and final visit). All patients were assessed at the 
first visit (baseline) and the end of the study period, scheduled 
for week 12. At the first visit, additional information was 
recorded, including demographics, previous therapy, and 
reasons for changing to BTFC.
All adverse events (AEs) were recorded as free-text 
entries, using a questionnaire. Symptoms were categorized 
by Medical Dictionary of Regulatory Activities (v 14.1) 
preferred term, and causality between AEs and treatment was 
rated as “definite,” “probable,” “possible,” “improbable,” “no 
relation,” “not assessable,” or “unknown.” Tolerability was 
assessed by both patient and physician using a four-point 
scale: “very good,” “good,” “moderate,” and “poor.” For 
patients who had received previous treatment, compliance 
with BTFC was compared with prior therapy and rated by 
physicians as “better,” “equal,” or “worse.”
Patients
Patients included in the studies had a diagnosis of POAG or 
OHT established by their treating physician according to 
local criteria. Patients were eligible for inclusion regardless 
of whether they had received prior IOP-lowering therapy.
Analysis
Analyses of patient demographic and safety data were per-
formed on the safety population, defined as all patients with 
any data documented. Change in IOP from baseline was 
calculated using data from all patients with complete data 
at both baseline and final visit. Data entry and analyses used 
the statistical software package SAS (v 9.1; SAS Institute, 
Cary, NC, USA) and Medidata software (Medidata, Kon-
stanz, Germany). Data quality checking allowed implausible 
data to be excluded from the analysis. Summary statistics 
included mean and median values, standard deviations (SDs), 
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minimum and maximum ranges, frequency distributions, and 
interquartile ranges. Change in IOP from baseline to final 
visit was analyzed using a two-sided paired t-test, taking as 
the null hypothesis that IOP did not change after 12 weeks 
of study treatment. A P value , 0.05 was considered statisti-
cally significant.
Results
All five studies took place between June 2008 and June 2011. 
In total, 5556 patients were recruited: 392 from Austria 
(40 sites), 1940 from France (231 sites), 1862 from Germany 
(339 sites), 698 from The Netherlands (84 sites), and 664 
from Switzerland (136 sites). Slightly more patients were 
female (54.9%) than male, and the mean age of participants 
was 67.6 ± 11.9 years (71.7% were .60 years old). Mean 
baseline IOP was 21.2 mmHg (Table 1) and most had a 
diagnosis of POAG (77.8%).
Mean time between enrollment and final study visit was 
15.8 ± 8.25 weeks. BTFC was prescribed once a day for each 
eye (in 93.3% of patients), as would be expected given the 
licensed use of this agent;18 2.7% received it twice daily (not 
licensed) and frequency was not stated for the remainder.
Prior therapy
Prior to switching to BTFC, 5164 patients (92.9%) were 
recorded as taking other medication at study entry (Table 2). 
The remaining 392 (7.1%) either received no previous 
 IOP-lowering therapy or had no information available 
 regarding prior medication. Most of the patients on prior 
therapy had previously received timolol (2420; 46.9%) either 
as monotherapy or in combination with other therapies. Of 
the 5154 patients on prior therapy, 3291 (63.7%) were taking 
a monotherapy, 1410 (27.3%) were taking two therapies, and 
463 (9.0%) were taking three or more therapies.
The most frequent reasons (more than one option could 
apply) given by physicians for switching to BTFC were insuf-
ficient IOP lowering on prior therapy (80.9%), progression of 
glaucoma-related damage (26.5%), unacceptable tolerability 
of prior therapy (11.9%), and lack of compliance with prior 
therapy (9.0%).
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Figure 1 Mean intraocular pressure (IOP) at baseline and final visit according to country, for patients with complete data only.
Notes: Error bars indicate standard deviations. *P , 0.0001, baseline versus final visit.
Table 1 Patient demographic data at baseline (n = 5556)
Mean ± SD n %*
Age (years) 67.6 ± 11.9 5396
Male 2469 44.4
Female 3050 54.9
Mean iOP (all patients), mmHg
 Right eye 21.2 ± 4.9 5432
 Left eye 21.2 ± 5.2 5421
Diagnosis
 POAG 4324 77.8
 OHT 1421 25.6
Patients on prior therapy 5164 92.9
Note: *Percentages may total more or less than 100%, due to missing data or 
selection of more than one option for some patients.
Abbreviations: iOP, intraocular pressure; OHT, ocular hypertension; POAG, 
primary open-angle glaucoma; SD, standard deviation.
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Effect on iOP
Baseline mean (±SD) IOP for the subset of patients with 
complete data for first and final visits was 21.4 ± 4.9 mmHg 
(n = 4134) and 21.5 ± 5.2 mmHg (n = 4130) for the right 
and left eyes, respectively. These values are similar to those 
shown in Table 1 for all recruited patients with baseline IOP 
data. At the final visit, mean IOP in this set of patients was 
reduced to 16.1 ± 3.3 mmHg and 16.0 ± 3.2 mmHg in the 
right and left eyes, respectively. This corresponds to a mean 
reduction in both eyes of −5.4 mmHg (P , 0.0001).
In patients with complete data for evaluation of efficacy 
(n = 1033), the target IOP as defined by the investigator was 
reached or bettered in 876 patients (84.8%). In 167 patients 
(16.2%), the IOP decreased but the target was not reached 
and 59 (5.7%) had no change or increased IOP.
The mean IOP reduction from baseline was similar 
across the five countries included in the studies: −5.8, −4.5, 
−5.7, −4.9, and −5.8 mmHg for centers in Austria, France, 
Germany, The Netherlands, and Switzerland, respectively 
(Figure 1). This reduction between first visit and final visit 
was significant for all patients with complete data across all 
the European countries (P , 0.0001).
The largest IOP reduction (−9.1 mmHg, mean of both 
eyes) was seen in patients (n = 311, right eye; n = 308, left 
eye) who had received no previous therapy (P , 0.0001), 
corresponding to a reduction of 36.4% in IOP from baseline 
(Figure 2A). However, BTFC also significantly reduced 
IOP in patients who had received prior monotherapy of 
a β-blocker (−5.6 mmHg) or the prostaglandin analogs 
latanoprost (−5.2 mmHg), travoprost (−5.7 mmHg), or 
bimatoprost 0.03% (−4.7 mmHg); P , 0.001 for all com-
parisons (Figure 2A). BTFC also produced additional IOP 
lowering in patients with complete data who had received 
prior therapy with other FCs, including dorzolamide/timolol 
FC (−4.7 mmHg), LTFC (−4.2 mmHg), TTFC (−4.4 mmHg), 
and brinzolamide/timolol FC (−2.2 mmHg) (Figure 2B). The 
overall mean reduction in these patients was −4.5 mmHg, 
corresponding to a reduction of 21.4% in IOP from  baseline. 
All additional IOP reductions for patients on prior FC 
therapy were significant (P , 0.0001), except for the small 
number of patients (n = 9) previously taking brinzolamide/
timolol FC.
Physicians rated the overall efficacy of BTFC on IOP 
reduction as “very good” or “good” in 88.7% of those patients 
for whom the evaluation data were available (n = 3111).
Tolerability and AEs
The majority of patients (5015/5556, 90.3%) did not report 
any AEs during treatment with BTFC (Table 3). AEs were 
recorded for 541 patients (9.7%), and the most common were 
conjunctival hyperemia (3.2%) and eye irritation (2.8%) 
(Table 3). Where evaluation data were available, BTFC 
tolerability was rated as “very good” or “good” by 92.5% 
of physicians (n = 4196) and 88.0% of patients (n = 4102) 
at week 12.
Three patients (0.05%) experienced serious adverse 
drug reactions. One patient was hospitalized for circula-
tory collapse, which was rated as possibly related to study 
 treatment. A second patient experienced life-threatening 
dyspnea immediately after instillation of BTFC, which the 
physician rated as probably related to study treatment. These 
reactions are also sometimes seen as a response to β-blocker 
therapy. A third patient suffered from conjunctival hyper-
emia and eye pruritus, classified as medically important by 
the physician, but with no recorded assessment of causal 
relation to treatment.
Physicians rated compliance as “better than” or “equal 
to” previous treatment in 96.3% of those patients with evalu-
ation data (n = 3823).
Discussion
These five observational studies aimed to evaluate the safety 
and efficacy of BTFC in routine clinical practice. In this 
pooled analysis of data from 5556 patients with POAG or 
OHT from 830 sites in five countries, patients treated with 
BTFC achieved a mean IOP reduction from baseline of 25% 
over a 12-week period. This reduction in IOP was statistically 
Table 2 Prior medications taken by .2% of patients at study 
entry, among those whose prior therapy was documented 
(n = 5164)*
Medication n % Active agent(s)
Xalatan® 1477 28.6 Latanoprost (0.005%)
Lumigan® 584 11.3 Bimatoprost (0.03%)
Travatan® 540 10.5 Travoprost (0.004%)
Cosopt® 498 9.6 Dorzolamide (0.2%), timolol (0.5%)
Xalacom® 422 8.2 Latanoprost (0.005%), timolol (0.5%)
Azopt® 280 5.4 Brinzolamide (1%)
Timolol 258 5.0 Timolol (0.1%, 0.25%, 0.5%)
Tim-Ophtal® 256 5.0 Timolol (0.1%, 0.25%, 0.5%)
DuoTrav® 241 4.7 Travoprost (0.004%), timolol (0.5%)
Alphagan® 184 3.6 Brimonidine (0.1%, 0.15%)
Timoptol® 178 3.4 Timolol (0.1%, 0.25%, 0.5%)
Trusopt® 158 3.1 Dorzolamide (2%)
Carteol® 153 3.0 Carteolol (1%)
Combigan® 141 2.7 Brimonidine (0.2%), timolol (0.5%)
Timoptic® 121 2.3 Timolol (0.1%, 0.25%, 0.5%)
Note: *Some patients previously received more than one intraocular pressure-
lowering medication.
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significant (P , 0.001). Similar mean IOP reductions were 
observed in all five European countries included in the study, 
thus it seems likely that these results would be borne out in 
similar populations in other European countries.
Most patients were switched to BTFC by their physician 
due to insufficient IOP lowering on their previous therapy 
(80.9%), and target IOP was reached or bettered in ∼85% of 
patients, most of whom (92.9%) were taking prior medica-
tion at the time of study entry. Significant reductions from 
baseline IOP were observed: 36.4% for no prior therapy, 
25.9% for prior β-blocker monotherapy, 24.4% for prior 
prostaglandin monotherapy, and 21.4% for prior FC therapy. 
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Figure 2 Mean intraocular pressure (IOP) reductions at final visit in (A) patients with no previous therapy or previous monotherapy and (B) patients with previous fixed 
combination therapy.
Notes: Bars represent the mean of right and left eye mean iOP differences from baseline. Error bars indicate standard deviations. Only data from patients with complete 
data are shown. *P , 0.0001, baseline versus final visit.
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Treatment with BTFC was also well tolerated, with ∼90% 
of patients experiencing no AEs, and compliance was rated 
as better than or equal to previous treatment by ∼96% of 
physicians.
This combined analysis includes a German observational 
study of 1862 patients in which continuation of BTFC therapy 
beyond the end of the study was 82.9%.17 In that study, an 
IOP # 16 mmHg was achieved by over half (56.2% right 
eyes, 54.8% left eyes) of the total patient population and 
in over a quarter of eyes studied (left and right); IOP was 
reduced further to #14 mmHg by week 12.
Three independent clinical trials have shown that BTFC 
has greater overall ability to lower IOP than LTFC or 
TTFC.13,15,19 In a meta-analysis that included those trials, 
IOP reduction from baseline was significantly greater with 
BTFC at all time points (9 am, noon, 4 pm, and diurnal 
curve) compared with TTFC and at 9 am, 4 pm, and over 
the diurnal curve compared with LTFC.16 Results from 
large clinical trials on the relationship between risk of 
progression and IOP1,2 suggest that the rate of progression 
may be reduced by as much as 10%–15% per mmHg of 
further IOP reduction.20 If so, modest reductions in IOP 
may result in considerable gains over an extended period, 
and the addition of one or more medications to achieve 
this extra IOP reduction may have significant benefits for 
the patient’s quality of life. This combined analysis of five 
observational studies demonstrates that BTFC can achieve 
additional IOP lowering in patients who have received prior 
therapy (monotherapy, adjunctive therapy, or FC) when 
used in clinical practice. Compared with their components 
used adjunctively, FCs are associated with less side effects 
and improved adherence.21
These studies were all open label and observational, and 
therefore have inherent limitations that affect interpretation 
of the results. Their design was uncontrolled and there was 
no washout period between the prior medications and the 
switch to BTFC. The studies were of relatively short dura-
tion, and although this was sufficient to evaluate changes 
in IOP levels, it was inadequate for evaluating long-term 
safety. Finally, the method of recording data using free-text 
entry may have allowed errors that could be difficult to 
detect. Nevertheless, combining data from five substantial 
studies provides a large body of data on the safety and 
efficacy of BTFC in clinical practice. The results confirm 
the findings of randomized clinical trials and demonstrate 
that BTFC is an effective choice for patients with POAG 
and OHT who have not achieved sufficient IOP lowering 
on their current therapy.
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